Global Ornithine Transcarbamylase (OTC) deficiency treatment market is estimated to be valued at US$ 810.4 million in 2023 and is expected to exhibit a CAGR of 4.25% during the forecast period (2023-2030). Increasing research and development activities for Ornithine Transcarbamylase (OTC) deficiency treatment by market players is expected to boost growth of the market over the forecast period. Moreover, increasing product approvals for Ornithine Transcarbamylase (OTC) deficiency treatment by regulatory bodies is expected to propel growth of the global Ornithine Transcarbamylase (OTC) deficiency treatment market over the forecast period
Global Ornithine Transcarbamylase (OTC) deficiency treatment market is segmented into Drug Type, Route of Administration, and Distribution Channel
Based on Drug Type, the market is segmented Buphenyl, Ravicti, Ammonul, and Others. Due to increased efficacy, drug cost, and improved patient compliance, Ravicti segment accounted for a significant share 35.2% in the global market in 2022.
In terms of Route of Administration, the global Ornithine Transcarbamylase (OTC) deficiency treatment market has been segmented into oral and intravenous.Market- Trends
On the basis of Distribution Channel, market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. Due to the higher number of prescriptions filled at thehospital pharmacies, favorable reimbursement scenario, strong supply chain management, and various patient assistance programme run by pharmaceutical companies, the hospital pharmacies segment expected to dominate the market over forecast period.
Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients